Italia markets closed

Hikma Pharmaceuticals PLC (HIK.L)

LSE - LSE Prezzo differito. Valuta in GBp (0.01 GBP).
Aggiungi a watchlist
1.918,50+38,00 (+2,02%)
Alla chiusura: 05:25PM GMT

Hikma Pharmaceuticals PLC

1 New Burlington Place
London W1S 2HR
United Kingdom
44 20 7399 2760
https://www.hikma.com

Settore/iHealthcare
SettoreDrug Manufacturers - Specialty & Generic
Impiegati a tempo pieno9.100

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Engineer Said Samih Taleb DarwazahExecutive Chairman2,22MN/D1957
Mr. Riad Ali MishlawiCEO & Director873,42kN/D1964
Mr. Mazen Samih Taleb DarwazahExecutive Vice Chairman & President of MENA1,82MN/D1958
Mr. Khalid Waleed Hosny Al NabilsiChief Financial OfficerN/DN/D1972
Patricia BousfieldChief Information OfficerN/DN/DN/D
Mr. Guy FeatherstoneAssociate Director of Investor RelationsN/DN/DN/D
Mr. Samuel ParkGeneral CounselN/DN/DN/D
Mr. Bassam Wael Rushdi Kanaan CFA, CPAExecutive Vice President of Corporate Development and M&AN/DN/D1965
Mr. Hussein Omar ArkhaghaChief People OfficerN/DN/DN/D
Ms. Susan RingdalExecutive Vice President of Strategic Planning & Global AffairsN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in GBp.

Descrizione

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.

Governance aziendale

L'ISS Governance QualityScore di Hikma Pharmaceuticals PLC al 1 marzo 2024 è 7. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 9; diritti degli azionisti: 7; retribuzione: 3.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.